Search results
Results From The WOW.Com Content Network
Gonorrhoea or gonorrhea, colloquially known as the clap, [7] is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. [8] Infection may involve the genitals, mouth, or rectum. [9] Gonorrhea is spread through sexual contact with an infected person, [1] or from a mother to a child during birth. [1]
Without treatment, about 10 percent of those with a chlamydial infection and 40 percent of those with a gonorrhea infection will develop PID. [2] [10] Risk factors are generally similar to those of sexually transmitted infections and include a high number of sexual partners and drug use. [2] Vaginal douching may also increase the risk. [2]
Fitz-Hugh–Curtis syndrome occurs almost exclusively in women, though it can be seen in males rarely. [5] It is complication of pelvic inflammatory disease (PID) caused by Chlamydia trachomatis (Chlamydia) or Neisseria gonorrhoeae (Gonorrhea) though other bacteria such as Bacteroides, Gardnerella, E. coli and Streptococcus have also been found to cause Fitz-Hugh–Curtis syndrome on occasion. [6]
The antibiotic, which would be the first new gonorrhea treatment approved in decades, could make it to market by 2025. ... leading to pelvic inflammatory disease and ectopic pregnancy.
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Gonorrhea, syphilis, and HIV should be tested for in those who have been infected. [2] Following treatment, people should be tested again after three months. [2] Chlamydia is one of the most common sexually transmitted infections, affecting about 4.2% of women and 2.7% of men worldwide. [4] [5] In 2015, about 61 million new cases occurred ...
Zoliflodacin (development codes AZD0914 and ETX0914) is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (). [1] It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases. [2]
Treatment typically consists of cephalosporin and fluoroquinolone antibiotics. [5] Gonococcemia is typically treated with intravenous or intramuscular cephalosporin antibiotics. [ 6 ] Approximately 10-30% of gonorrheal infections present with a co-infection of chlamydia , so it is common to add a one-time dose of oral azithromycin or ...